MiniMed Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MMED in the last 30 days.
See all $MMED insider activity →Medtronic (MDT) announced a final exchange ratio of 4.5939 shares of MiniMed (MMED) for each Medtronic share in its split-off offer. Up to 225.4 million MiniMed shares will be exchanged, with proration if oversubscribed. The offer expires October 9, 2026, unless extended.
MiniMed (MMED) presented clinical trial data showing that users of its Smart MDI system who responded to more alerts had 8.1% more Time in Range and 0.6% lower HbA1c. The six-month study involved 143 people with type 1 diabetes. The Smart MDI system connects a smart insulin pen with a continuous glucose monitor via an app, providing dose calculations and alerts.
Truist initiated a Buy rating for MiniMed (MMED) with a $29 price target, citing improved investment, strategy, and new product launches. The company, spun off from Medtronic (MDT), is expected to maintain and grow its market share in insulin-intensive diabetes segments. Truist forecasts 10% revenue growth and potential EPS doubling in two years.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning MMED (MiniMed Group, Inc.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 0 bearish.
Recent MMED coverage spans earnings, mergers & acquisitions and corporate actions.
MiniMed will become a standalone public company with a defined share count, affecting its market cap and liquidity.
Positive clinical data may boost investor confidence in MiniMed's Smart MDI system.
Analyst upgrade suggests significant upside potential.
Buy initiation could boost MMED.
Analyst upgrades show optimism despite cash burn; short interest remains high.
AlphAI scores every news story that mentions MMED with an AI model for sentiment and relevance, and aggregates insider trades from MiniMed Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medtronic (MDT) announced a final exchange ratio of 4.5939 shares of MiniMed (MMED) for each Medtronic share in its split-off offer. Up to 225.4 million MiniMed shares will be exchanged, with proration if oversubscribed. The offer expires October 9, 2026, unless extended.
2 min readMiniMed (MMED) presented clinical trial data showing that users of its Smart MDI system who responded to more alerts had 8.1% more Time in Range and 0.6% lower HbA1c. The six-month study involved 143 people with type 1 diabetes. The Smart MDI system connects a smart insulin pen with a continuous glucose monitor via an app, providing dose calculations and alerts.
2 min readTruist initiated a Buy rating for MiniMed (MMED) with a $29 price target, citing improved investment, strategy, and new product launches. The company, spun off from Medtronic (MDT), is expected to maintain and grow its market share in insulin-intensive diabetes segments. Truist forecasts 10% revenue growth and potential EPS doubling in two years.
2 min readAnalysts made several rating changes and price target adjustments. JPMorgan upgraded CoreWeave, Welltower, and Macerich, while Citi downgraded Dropbox. Bernstein upgraded Quanta Services, and Morgan Stanley initiated Imax and Nvidia with overweight ratings. Other notable moves include upgrades for Arcturus Therapeutics, Dollar General, and The Brink's Company, and initiations for NeOnc Technologies, Energy Services of America, BayCom, Avidbank, and SpaceX.
3 min readMiniMed Group (MMED) reported Q1 2027 revenue of $843M, up 16.6%, and raised full-year guidance. Analysts raised targets, citing pipeline progress and strong product momentum. However, adjusted EBITDA margin was 9.9%, and free cash flow was negative $90M due to separation costs and other expenses.
2 min readMiniMed Group, Inc. (NasdaqGS:MMED) has been added to the S&P Healthcare Equipment Select Industry Index. The company's stock has seen a 5-day change of 21.79 USD, with a 1st Jan change of -1.09% and -3.16%. Medtronic recently launched an exchange offer for shareholders to receive MiniMed shares at a discount.
1 min readMiniMed Group (MMED) reported Q1 revenue of $843M, up 15.8% organically, beating expectations. U.S. revenue grew 13.1%, driven by the MiniMed Flex launch. The company raised fiscal 2027 revenue guidance to ~10.5% growth, citing strong pump and CGM demand. Despite FX and separation costs, adjusted gross margin was 55.9%, and adjusted EBITDA margin was 9.9%.
3 min readMedtronic (MDT) is offering shareholders the chance to exchange their shares for MiniMed (MMED) stock, as it divests its final stake in the diabetes tech company. MiniMed went public in March, raising $538 million. Medtronic plans to sell 80.1% of MiniMed's stock at a 7% discount, with shareholders receiving about $107.53 of MiniMed stock for every $100 of Medtronic.
2 min readMiniMed (MMED) filed a Form S-4 with the SEC regarding Medtronic's (MDT) offer to exchange up to 80.1% of MiniMed shares for Medtronic shares. Medtronic currently owns 89.86% of MiniMed. If completed, Medtronic will no longer hold an equity stake in MiniMed. The exchange offer is subject to SEC approval and certain conditions.
2 min readMiniMed (MMED) reported Q3 revenue growth of 15.8% to $843M, driven by strong sales of its new Flex insulin pump. US pump sales rose over 20% YoY, and international markets saw significant growth. The company raised its full-year revenue growth outlook to 10.5%. However, adjusted EBITDA margin was 9.9%, and free cash flow was negative $90M due to separation costs and other expenses. Management expects future product launches and continued growth.
3 min read
